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the following outcomes after controlling for individuals’ observed and unobserved 
characteristics together with their CMS risk scores: 1) Adjusted MLR spikes up at the 
same time as the share of enrollees who die also spikes upward; (2) Adjusted expenses 
paid by the plan on behalf of enrollees who died while enrolled are much higher than 
the CMS payments to the plan for the same enrollees in the month of death and in 
the 4 to 6 months prior to death; and 3) We found that death rates in each calendar 
month explain about 30 to 40% of adjusted MLR. CONCLUSIONS: The results show 
that Medicare Part A utilization and expenditures have a limited role in the increasing 
trend of adjusted MLR for beneﬁciaries who survive through the enrollment period. 
However, we ﬁnd a positive, stronger and statistically signiﬁcant correlation between 
inpatient visits and the expenses for enrollees who died while enrolled. The correlation 
remains signiﬁcant up to 24 months prior to the death of an enrollee.
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OBJECTIVES: In Canada, the CDR conducts health technology assessments and 
provides funding recommendations to participating jurisdictions. These recommenda-
tions are publically available but little research has been conducted to understand 
the rationale behind these decisions. Furthermore, the acceptable ICER for the CDR 
is not published but is generally perceived to be $50,000/QALY. This study was 
conducted to analyze published CDR recommendations to determine if speciﬁc factors 
inﬂuence decision-making. METHODS: For this abstract, four variables were con-
sidered for 143 recommendations (December 2003 to October 2009). These variables 
include manufacturer-submitted ICER, ﬁrst-in-class status, therapeutic categories, 
and request for reconsiderations. RESULTS: Thirty-seven of 143 CDR recommenda-
tions reported ICER values and were analyzed. The average ICER was $47,900 ± 
29,100/QALY (N = 20) for “List” recommendations and $91,400 ± 52,300/QALY 
(N = 17) for “Do not list” recommendations (p < 0.05). A trend towards statistical 
signiﬁcance for an effect of ﬁrst-in-class on receiving negative recommendation was 
observed (Fisher’s exact test, p = 0.0873). There appeared to be an overall effect 
of therapeutic category on recommendation (χ2: 36.213, df: 11, p < 0.0001). An 
effect of requests for reconsideration on recommendation outcome was also observed 
(Fisher’s exact test, p < 0.0001). CONCLUSIONS: From the pharmacoeconomics 
perspective, the average ICER of $47,900/QALY is in alignment with the perceived 
limit, although majority of reviews did not have a reported ICER. Nonetheless, 
considerable variation in the ICER indicated additional factors inﬂuence CDR 
decision-making. Being ﬁrst-in-class had small but non-signiﬁcant inﬂuence on CDR 
recommendation. Therapeutic category had signiﬁcant inﬂuence on recommendations 
although the sample size was small and further investigation is needed to determine 
the cause. Finally, requests for reconsideration did little to inﬂuence the initial CDR 
recommendation. The overall ﬁndings suggested that while the ICER may be an 
important input into the decision-making process, careful examination of other 
factors will be needed to further understand the relative inﬂuence of the ICER on 
ﬁnal CDR recommendations.
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OBJECTIVES: In order to meet the cost-effectiveness requirements of the National 
Institute for Health and Clinical Excellence (NICE), manufacturers are increasingly 
utilizing innovative pricing agreements (IPAs). This research aims to identify all such 
agreements from published NICE appraisals and to provide recommendations to 
pharmaceutical companies on their utility. METHODS: All completed NICE technol-
ogy appraisals published from 2006 to 2009 were reviewed and any submission in 
which the guidance included an IPA was identiﬁed. An IPA was deﬁned as the manu-
facturer providing a pre-deﬁned reduction of the overall cost of treatment based on 
risk sharing or rebate schemes. RESULTS: The inclusion of IPAs in NICE guidance 
is increasing over time. Of 18 appraisals published in 2006 none included an IPA. 
There was an IPA element in 5% (1/21) appraisals in 2007, increasing to 7% of 
appraisals (2/27) in 2008, and 22% (4/18) in 2009. Of the 7 IPAs identiﬁed from 
2006 to 2009, 5 were for oncology products, the others being for psoriasis and age-
related macular generation. The form of the IPAs could be broadly categorized into 
1) a rebate across a speciﬁc patient population (N = 3); 2) drug provided free for 
patients remaining on treatment beyond a speciﬁc point (N = 2); 3) provision of free 
ﬁrst cycle of treatment (N = 1) and 4) cost matched to existing treatment (N = 1). 
IPAs were included through initial proposals to the Department of Health by the 
manufacturer (N = 3), as part of the revised manufacturer’s model following the initial 
review (N = 3) and through proposals by the NICE committee (N = 1). CONCLU-
SIONS: Pharmaceutical companies are increasingly using innovative price agreements 
in their NICE submissions. Such agreements are mutually beneﬁcial and acceptable to 
both parties and provide an opportunity for companies to demonstrate their conﬁ-
dence in the value claims of speciﬁc therapies.
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OBJECTIVES: The study was conducted to describe the characteristics and quality of 
health economic (including pharmacoeconomics) evaluation research studies related 
to Nigeria. METHODS: A literature review was conducted to identify health economic 
evaluation articles. Main databases (e.g., PUBMED, MEDLINE) were used to search 
for economic analyses. The study included only original economic evaluations that 
pertained to Nigeria, addressed a health-related topic (e.g., pharmacy) and were 
complete peer-reviewed publications in the English language. Two reviewers indepen-
dently evaluated and scored each article in the ﬁnal sample using a data collection 
form. RESULTS: The 44 identiﬁed articles were published in 34 different journals 
mostly based outside of Nigeria between 1988 and 2009. On average, each article 
was written by four authors. Most (98%) ﬁrst authors had medical/clinical training 
and resided in Nigeria (75%) at the time of publication of the study. Based on a 1 to 
10 scale, with 10 indicating the highest quality, the mean quality score for all studies 
was 7.29 (SD = 1.21) and 59 percent of the articles were of fair quality (score 5–7). 
The quality of articles was statistically signiﬁcantly related (p < 0.05) to the country 
of residence of primary author (non-Nigeria = higher), the country of journal 
(non-Nigeria = higher), primary objective of the study (economic evaluation as the 
objective = higher), and type of economic analysis conducted (full economic evalua-
tions = higher). The quality of the articles was not signiﬁcantly related to the sample 
size, type of data (primary vs secondary), number of authors, type of publication, year 
of publication, study perspective and primary health intervention (p > 0.05). CON-
CLUSIONS: The conduct of health economics (including pharmacoeconomics) evalu-
ation research in Nigeria is limited and about two-thirds of published articles were of 
fair quality. More and better quality health economics research in Nigeria is 
warranted.
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OBJECTIVES: This study aimed to summarize the current status and desired compo-
nents of pharmacoeconomics and outcomes research PhD programs. METHODS: 
Using the educational directory on the ISPOR website, 32 PhD programs were identi-
ﬁed and contacted. Programs’ participation in an online survey was requested if their 
program focused on pharmacoeconomics, outcomes research or related ﬁelds. The 23 
question survey asked for speciﬁc information about their program, faculty, staff and 
students as well as their insight on factors important to such training. RESULTS: Of 
the 32 programs contacted, 14 (44%) responded, with two stating that their program 
did not ﬁt the inclusion criteria. Of the ﬁve programs offering degrees in pharmaceuti-
cal outcomes or economics speciﬁcally, 1994 was the earliest year of establishment 
and 2001 the most recent. The remaining programs provided such training within 
broader and more established programs. On average, programs had seven full-time 
faculty, four staff and 15 current PhD students. When asked about the ideal number 
for a program’s success, 8 full-time faculty and 17 students were desired. Historically, 
51% of students had a previous Master’s degree, 36% had a professional degree and 
about 16% had a Bachelor’s degree only. The mean time for completion of coursework 
was 2.7 years and 4.9 years to graduation. After graduation, 32% of students take a 
job in academia, 41% take a job in industry and 10% take a post-doctoral position. 
When asked about factors contributing to a program’s success, reputation of faculty’s 
research was thought to be most important. For students entering a PhD program in 
this ﬁeld, faculty’s mentoring experience and reputation was considered most impor-
tant. CONCLUSIONS: Programs offering speciﬁc training in this ﬁeld have only been 
in existence about 15 years. Programs appear to be growing, as desired number of 
faculty and students are higher than average numbers existing presently.
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OBJECTIVES: The US Food and Drug Administration (FDA) proposed labeling 
changes to be implemented by April 29, 2010 that would improve inappropriate 
and excessive use of over-the-counter (OTC) internal analgesic, antipyretic and anti-
rheumatic drugs (IAAA). This study examined the attitude and knowledge of phar-
macists about these labeling changes as pharmacists regularly advise on such products 
to consumers. METHODS: A prospective, cross-sectional study was conducted by 
surveying pharmacists working in a 15 mile radius of the Texas Medical Center. 
The survey instrument consisted of a 25 item questionnaire. Cronbach’s alpha (0.89) 
was used to assess the internal consistency of the instrument. Two-sided studentized 
t-test (μ = 3, α = 0.05) and descriptive statistics were used to analyze pharmacist’s 
attitude and awareness respectively for each individual parameter pertaining to the 
labeling changes. RESULTS: A total of 51 (out of 70) community pharmacist par-
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ticipated in this study. Of the respondents 55% were females, 69% worked in a 
chain pharmacy, with an average 11 years of work experience. 65% of the respon-
dents were aware of the labeling changes introduced by the FDA. Attitude of phar-
macists towards all the speciﬁc labeling changes introduced for acetaminophen and 
NSAIDs were positive. Pharmacists strongly and signiﬁcantly agreed (p < 0.001) 
that labeling changes like highlighting ingredient name or mentioning it in bold print 
(3.84 ± 1.08), appearance of “See New Warnings” statement on the principal display 
panel for one year (3.96 ± 1.06), age speciﬁc warnings for adults and for children 
below 12 years of age (4.12 ± 1.19), mentioning the maximum daily dosage units 
of acetaminophen under liver warnings (4.31 ± 1.06), will be useful for patients. 
CONCLUSIONS: The results indicate that majority of pharmacists agreed with 
FDA’s labeling changes for OTC IAAA drug products. More information regarding 
these changes should be provided to pharmacists and consumers to increase appro-
priate use of these products.
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OBJECTIVES: Experience indicated that the quality of economic evaluations submit-
ted in reimbursement dossiers and critical appraisals are heterogeneous. The objective 
of this study was to analyse the quality of submitted economic studies and related 
critical appraisal processes and to develop a policy-relevant, publicly available Slovak 
critical appraisal checklist for improving the quality of economic evaluation and 
budget impact analyses for reimbursement submission of dossiers concerning to drugs 
and medical devices. METHODS: We created a working group to review previously 
submitted economic evaluations and related critical appraisals in order to identify 
potential technical and methodological problems. The working group consisted of 
independent academic experts who scrutinized previous submissions and critical 
appraisals and developed a new checklist. Overall 50 economic evaluations submitted 
for reimbursement of drugs and medical devices in 2007–2009 were scrutinized. 
RESULTS: Evidence suggests that Slovak pharmaceutical expenditures do not result 
in the most cost-effective outcomes. Several potentially not cost-effective pharmaceu-
ticals have been reimbursed in Slovakia. Economic evaluations of drugs and medical 
devices are mandatory but the quality of evaluations and critical appraisals are rather 
poor. Therefore in addition to the available Slovak health economic evaluation guide-
lines a detailed checklist for appraisal processes have to be prepared. Our analysis 
shows that the simpliﬁed questionnaire, which is currently used for the critical 
appraisal process within Slovakia should be replaced by a new Slovak critical appraisal 
checklist, which will be detailed enough to address the most common problems in the 
local economic evaluations and budget impact analyses for decision making process. 
CONCLUSIONS: The transparent method of technology assessment can improve the 
consistency of reimbursement decisions making related to drugs and medical devices 
in Slovakia. The current checklist for critical appraisal is not sufﬁcient enough and 
there is signiﬁcant room for improvement in this ﬁeld.
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OBJECTIVES: The objective of this study was to evaluate outcomes of a bedside 
barcode technology intervention on medication administration time in an intensive 
care unit (ICU). METHODS: A prospective observational time-and-motion experi-
mental study was conducted by considering two medication administration processes 
(a paper based approach vs. the bedside barcode system) in a large 500+ bed hospital 
setting. Medication administration by the nurse was operationalized as activities such 
as direct or indirect patient care, administration, and miscellaneous. Time devoted to 
complete these medication administration activities were measured separately by 
means of two pre-calibrated stop watches. Complexity factors of medication admin-
istration (age, sex, body-weight, comorbidities, number of drugs administered, and 
length of ICU stay) were included in linear regression model to predict time required 
for each of those medication administration activities. RESULTS: One hundred and 
ﬁfty-one electronically documented medication administrations with the bedside 
barcode system were evaluated Mean times of direct patient care activity (182.32 ± 
131.68 seconds) and administration activity (59.83 ± 74.53 seconds) during bedside 
barcode medication administration improved signiﬁcantly in comparison with paper 
based approach. In the bedside barcode system, signiﬁcant (p < 0.05) predictors of 
time associated with direct patient care activity was number of drugs administered, 
for indirect patient care activity was comorbidities, and for administration activity 
was length of ICU stay. CONCLUSIONS: Variables that predict medication admin-
istration time in the bedside barcode system were different across the categorized 
activities. To develop and implement efﬁcient systems, such variables should be moni-
tored and controlled as high cost technology is adopted by hospitals.
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OBJECTIVES: A goal of evidence review is to inform policy decisions such as for 
insurance. This study examines whether and how U.S. payers use evidence reviews in 
policy decisions for personalized medicine. METHODS: We used literature review, 
focused interviews and a Roundtable meeting. Literature review was used to review 
and compare seven evaluation frameworks available to guide payer decisions: Blue 
Cross Blue Shield Technology Evaluation Center (BCBS TEC); ECRI Institute, Evalu-
ation of Genomic Applications in Practice and Prevention, Institute for Clinical and 
Economic Review, Hayes, Inc., Up-To-Date and United States Preventive Services Task 
Force. Seventeen interviews of health plan executives were used to identify whether 
and how these frameworks were used in policy decisions made by individual plans. A 
meeting that included interviewees and other thought leaders was used to discuss 
similarities and differences across payers in whether and how formal evaluations 
informed policy. The study focused on personalized medicine, the use of genetics or 
genomics to guide health care decisions. RESULTS: We found that frameworks vary 
in: purpose, questions of interest, range of evidence included, availability, and capac-
ity. All frameworks were used by at least one payer to inform policy decisions with 
one framework (BCBS TEC) used by all but one interviewed payer. All payers reported 
using multiple frameworks. Payers reported key gaps in frameworks including: lack 
of evidence on health care system factors, lack of timeliness and lack of breadth. 
Across payers the range of evidence used to inform decisions was believed to result in 
policy variation. In particular, when clinical evidence is uncertain but decisions 
needed, payers reported using nonclincal evidence to help guide decisions. CONCLU-
SIONS: Payers use evidence reviews to inform policy decisions but no single frame-
work is sufﬁcient. Key ways to improve reviews for insurance policy decisions might 
focus on balancing the tension between comprehensiveness and timeliness.
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OBJECTIVES: Health technology assessment (HTA) is used to evaluate health care 
technologies (e.g., pharmaceuticals, medical devices, and diagnostics) with respect to 
cost and their projected impact on patient outcomes and society. Currently, there is 
an ongoing initiative by the International Society for Pharmacoeconomics and Out-
comes Research (ISPOR) to develop Road Maps that describe the utilization of HTA 
in health care. The purpose of this study was to develop models for HTA decision-
making structures along with reimbursement road maps for several countries. 
METHODS: Members of the ISPOR Special Interest Group (SIG) for HTA contacted 
key individuals in several countries, including: Austria, Demark, Hungary, Ireland, 
France, Germany, Denmark, UK, Sweden, Australia, Canada, Taiwan, United States, 
and others. Once decision models and corresponding reimbursement road maps were 
developed within designated HTA subgroups, the information was disseminated to all 
HTA committee members for review. After review, the decision models were sent to 
key stakeholders in each selected country for review and validation. RESULTS: Deci-
sion-making structures and review processes for reimbursement were developed for 
the selected counties. Key decision makers and/or third-party payers (e.g., person or 
organization) were identiﬁed and deﬁned in accordance with their role in the reim-
bursement process. Evaluators were deﬁned as individuals or organizations that 
provide input into the decision-making process regarding HTA development, but may 
not be responsible for ﬁnal coverage and payment decisions. CONCLUSIONS: Deci-
sion structures for reimbursement (e.g., coverage, coding, and payment) vary accord-
ing to the type of product (e.g., pharmaceutical, medical device, and diagnostic), the 
individual country and in some instances, by regions within the country. The HTA-SIG 
will continue to identify and validate HTA decision pathways for reimbursement 
within each country to provide guidance to manufacturers and policy makers in a way 
that optimizes efﬁciencies and supports the ongoing societal needs for access to emerg-
ing technologies.
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OBJECTIVES: The assessment of medical technologies in hospitals is often an unstruc-
tured not transparent process, only involving a small group of decision makers. To 
overcome barriers while discussing or implementing decisions, a clear communication 
